Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance
K Fu, F Xie, F Wang, L Fu - Journal of Hematology & Oncology, 2022 - Springer
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the preferential
options for advanced non-small cell lung cancer (NSCLC) patients harboring EGFR …
options for advanced non-small cell lung cancer (NSCLC) patients harboring EGFR …
Efficacy and safety of first line treatments for patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: systematic review and …
YI Zhao, J Liu, X Cai, Z Pan, J Liu, W Yin, H Chen, Z Xie… - Bmj, 2019 - bmj.com
Objective To compare the efficacy and safety of first line treatments for patients with
advanced epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer …
advanced epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer …
Lazertinib Versus Gefitinib as First-Line Treatment in Patients With EGFR-Mutated Advanced Non–Small-Cell Lung Cancer: Results From LASER301
BC Cho, MJ Ahn, JH Kang, RA Soo… - Journal of Clinical …, 2023 - ascopubs.org
PURPOSE Lazertinib is a potent, CNS-penetrant, third-generation epidermal growth factor
receptor (EGFR) tyrosine kinase inhibitor. This global, phase III study (LASER301) …
receptor (EGFR) tyrosine kinase inhibitor. This global, phase III study (LASER301) …
Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open …
S Lu, J Zhou, H Jian, L Wu, Y Cheng, Y Fan… - The Lancet …, 2023 - thelancet.com
Summary Background Befotertinib (D-0316) is a novel, selective oral third-generation
epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor. This phase 3 trial …
epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor. This phase 3 trial …
Overall survival in advanced epidermal growth factor receptor mutated non-small cell lung cancer using different tyrosine kinase inhibitors in The Netherlands: a …
RGP Gijtenbeek, RAM Damhuis… - The Lancet Regional …, 2023 - thelancet.com
Background Clinical guidelines advise osimertinib as preferred first line treatment for
advanced epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer …
advanced epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer …
Advances in the management of non-small-cell lung cancer harbouring EGFR exon 20 insertion mutations
Epidermal growth factor receptor (EGFR) mutation is one of the key oncogenic mutations in
non-small-cell lung cancer with adenocarcinoma histology. Exon 19 deletions and exon 21 …
non-small-cell lung cancer with adenocarcinoma histology. Exon 19 deletions and exon 21 …
[HTML][HTML] Central nervous system efficacy of furmonertinib (AST2818) versus gefitinib as first-line treatment for EGFR-mutated NSCLC: results from the FURLONG study
Y Shi, G Chen, X Wang, Y Liu, L Wu, Y Hao… - Journal of Thoracic …, 2022 - Elsevier
Introduction Furmonertinib (AST2818) is a pan-EGFR tyrosine kinase inhibitor with central
nervous system (CNS) antitumor activity. We report the CNS efficacy of furmonertinib …
nervous system (CNS) antitumor activity. We report the CNS efficacy of furmonertinib …
[HTML][HTML] The advance of the third‑generation EGFR‑TKI in the treatment of non‑small cell lung cancer
Z Cheng, H Cui, Y Wang, J Yang… - Oncology …, 2024 - build.spandidos-publications.com
Lung cancer is currently the second most common type of cancer with the second incidence
rate and the first mortality rate worldwide. Non‑small cell lung cancer (NSCLC) accounts for …
rate and the first mortality rate worldwide. Non‑small cell lung cancer (NSCLC) accounts for …
Therapy for stage IV non–small cell lung cancer with driver alterations: ASCO living guideline, version 2023.3
IA Jaiyesimi, NB Leighl, N Ismaila, K Alluri… - Journal of clinical …, 2024 - ascopubs.org
Living guidelines are developed for selected topic areas with rapidly evolving evidence that
drives frequent change in recommended clinical practice. Living guidelines are updated on …
drives frequent change in recommended clinical practice. Living guidelines are updated on …
A real-world study of the efficacy and safety of furmonertinib for patients with non-small cell lung cancer with EGFR exon 20 insertion mutations
H Sa, Y Shi, C Ding, K Ma - Journal of Cancer Research and Clinical …, 2023 - Springer
Background Furmonertinib is a novel third-generation epidermal growth factor receptor
(EGFR) tyrosine kinase inhibitor (TKI). A phase Ib study (FAVOUR, NCT04858958) initially …
(EGFR) tyrosine kinase inhibitor (TKI). A phase Ib study (FAVOUR, NCT04858958) initially …